Sonoma Pharmaceuticals (SNOA) Gross Profit (2010 - 2025)

Sonoma Pharmaceuticals' Gross Profit history runs 16 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• In Q4 2025, Gross Profit rose 29.92% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $6.8 million (up 34.49% YoY), while the FY2025 annual figure was $5.5 million, up 15.17% from the prior year.
• Gross Profit was $1.6 million for Q4 2025 at Sonoma Pharmaceuticals, down from $2.1 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $2.1 million in Q3 2025 to a low of -$194000.0 in Q1 2021.
• Historically, Gross Profit has averaged $1.2 million across 5 years, with a median of $1.3 million in 2024.
• The sharpest annual moves came in 2021 and 2023: Gross Profit plunged 111.74% in 2021, then surged 800.0% in 2023.
• A 5-year view of Gross Profit shows it stood at $1.2 million in 2021, then tumbled by 30.92% to $831000.0 in 2022, then jumped by 75.69% to $1.5 million in 2023, then retreated by 13.01% to $1.3 million in 2024, then increased by 29.92% to $1.6 million in 2025.
• The last three Gross Profit figures came in at $1.6 million (Q4 2025), $2.1 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.